Home › Research › Getting a diagnosis
The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia
Marta Campagnolo, Eleonora Fiorenzato, Giulia Musso, Valentina Misenti, Simone Cauzzo, Annachiara Cagnin, Roberta Biundo, Cinzia Bussè et al.. Journal of the Neurological Sciences, 2025-07-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The complexity of neurodegenerative disorders necessitates an integrative approach that incorporates morphological, functional, and molecular biomarkers. The advent of highly sensitive single-molecule array (Simoa®) assays has significantly enhanced the accuracy of blood-based biomarker quantification, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181). This study evaluates the diagnostic utility of these biomarkers in neurodegenerative diseases. We analyzed data from 279 individuals from the PADUA-CESNE cohort: 120 with Parkinson's disease (PD), 88 with Alzheimer's disease (AD), 16 with frontotemporal dementia (FTD), 11 with multiple system atrophy (MSA), 14 with progressive supranuclear palsy (PSP), and 30 cognitively unimpaired controls. NfL levels were significantly lower in PD and AD compared to atypical parkinsonisms and FTD, effectively distinguishing MSA and PSP from controls. NfL also negatively correlated with Montreal Cognitive Assessment (MoCA) scores in AD and PD, indicating its association with cognitive decline. Elevated GFAP levels were observed in both PD and AD and inversely correlated with global cognition. Combining GFAP and p-tau181 improved AD differentiation from PD and other parkinsonian disorders, while the integration of all three biomarkers facilitated the distinction between AD and FTD. Notably, lower NfL levels (<20 ng/L) in conjunction with elevated p-tau181 were indicative of AD, whereas NfL levels below 40 ng/L were suggestive of PD. In conclusion, NfL serves as a sensitive indicator of neurodegeneration, albeit with limited specificity. However, by establishing biomarker concentration thresholds and integrating complementary biomarkers, blood-based assays may enhance the differential diagnosis of neurodegenerative diseases, providing valuable clinical insights.
What this study adds
Evidence grade: Moderate
The record lists 279 participants. In this cohort, blood-based biomarkers including NfL, GFAP and p-tau181 helped distinguish between neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease and atypical parkinsonisms. The study evaluates diagnostic utility only and reports no treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Campagnolo, M., Fiorenzato, E., Musso, G., Misenti, V., Cauzzo, S., Cagnin, A., et al. (2025). The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia. Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2025.123617
Vancouver
Campagnolo M, Fiorenzato E, Musso G, Misenti V, Cauzzo S, Cagnin A, et al. The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia. Journal of the Neurological Sciences. 2025. doi:10.1016/j.jns.2025.123617. PMID: 40682931.
BibTeX
@article{campagnolo2025-40682931,
author = {Campagnolo, Marta and Fiorenzato, Eleonora and Musso, Giulia and Misenti, Valentina and Cauzzo, Simone and Cagnin, Annachiara and Biundo, Roberta and Bussè, Cinzia and others},
title = {{The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia}},
journal = {Journal of the Neurological Sciences},
year = {2025},
doi = {10.1016/j.jns.2025.123617},
pmid = {40682931},
url = {https://doi.org/10.1016/j.jns.2025.123617}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The advent of highly sensitive single-molecule array (Simoa®) assays has significantly enhanced the accuracy of blood-based biomarker quantification, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181).
- NfL levels were significantly lower in PD and AD compared to atypical parkinsonisms and FTD, effectively distinguishing MSA and PSP from controls.
- In conclusion, NfL serves as a sensitive indicator of neurodegeneration, albeit with limited specificity.
Why it matters
In this cohort, blood-based biomarkers including NfL, GFAP and p-tau181 helped distinguish between neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease and atypical parkinsonisms. The study evaluates diagnostic utility only and reports no treatment or cure.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Participants279
- Evidence strengthModerate
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the Neurological Sciences) |
| Journal's citation record | 2 / 4 | Journal of the Neurological Sciences: journal h-index 233 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 279 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 17 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 10.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Angelo Antonini: h-index 105 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Padua: institution h-index 1,158 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40682931) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jns.2025.123617
- PubMed: 40682931
- Original source →
- Free full text: Journal of the Neurological Sciences →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Getting a diagnosis from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.